Exposure to and activation of dietary heterocyclic amines in humans.
Lynch
A M
AM
Department of Clinical Pharmacology, Royal Postgraduate Medical School, London, UK.
Murray
S
S
Gooderham
N J
NJ
Boobis
A R
AR
D000818:Animals; D001682:Biological Availability; D001711:Biotransformation; D002273:Carcinogens / Q000009:adverse effects / Q000032:analysis / Q000493:pharmacokinetics*; D015179:Colorectal Neoplasms / Q000139:chemically induced; D003296:Cooking; D019388:Cytochrome P-450 CYP1A2 / Q000378:metabolism; D018736:DNA Adducts; D004032:Diet / Q000009:adverse effects; D006571:Heterocyclic Compounds / Q000009:adverse effects / Q000032:analysis / Q000493:pharmacokinetics*; D006358:Hot Temperature; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000032:analysis / Q000493:pharmacokinetics*; D008099:Liver / Q000378:metabolism; D008460:Meat / Q000032:analysis; D009152:Mutagenicity Tests; D009153:Mutagens / Q000009:adverse effects / Q000032:analysis / Q000493:pharmacokinetics*; D011506:Proteins / Q000378:metabolism; D011804:Quinolines / Q000009:adverse effects / Q000032:analysis / Q000493:pharmacokinetics*; D011810:Quinoxalines / Q000009:adverse effects / Q000032:analysis / Q000493:pharmacokinetics*; D051381:Rats; D018570:Risk Assessment
D002273:Carcinogens; D018736:DNA Adducts; D006571:Heterocyclic Compounds; D007093:Imidazoles; D009153:Mutagens; D011506:Proteins; D011804:Quinolines; D011810:Quinoxalines; C036990:2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline; C049584:2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; D019388:Cytochrome P-450 CYP1A2; C036989:2-amino-3,4-dimethylimidazo(4,5-f)quinoline